BridgeBio Pharma Patent-Cliff Exposure & CMS Drug Spending Portfolio

BridgeBio Pharma (Palo Alto, CA): 1 reconciled FDA prescription therapies, $870K 2024 CMS Part D & Medicaid spend, and $18,759 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterPalo Alto, CA
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2039-01-01
2024 CMS Total Public Spend$870K
2024 Medicare Part D Spend$870K
2024 Medicaid Spend$0
California HCAI SB 17 FilingsSpecialty launch notice ($18,759 intro WAC)